NASDAQ : JUNS
Jupiter Neurosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.37 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.12M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.05M |
| Enterprise Value | 3.27M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.32M |
| Shares Outstanding | 1.32M |
| Shares Change (YoY) | +16.80% |
| Shares Change (QoQ) | +18.61% |
| Owned by Insiders (%) | 16.67% |
| Owned by Institutions (%) | 5.28% |
| Float | 965,804 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.69 |
| Forward PS | 0.25 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 51.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.66 |
| Quick Ratio | 0.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,888.70% |
| Return on Assets (ROA) | -159.56% |
| Return on Invested Capital (ROIC) | -420.59% |
| Return on Capital Employed (ROCE) | 6,098.14% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $12,939 |
| Profits Per Employee | -$1.84M |
| Employee Count | 5 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -97.81% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 20.24 |
| Relative Strength Index (RSI) | 39.80 |
| Average Volume (20 Days) | 69,991 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 38,578 |
| Short Previous Month | 35,426 |
| Short % of Shares Out | 2.93% |
| Short % of Float | 3.99% |
| Short Ratio (days to cover) | 0.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 64,693 |
| Gross Profit | -1.82M |
| Operating Income | -9.81M |
| Pretax Income | -9.20M |
| Net Income | -9.20M |
| EBITDA | n/a |
| EBIT | -9.81M |
| Loss Per Share | -$18.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.52M |
| Total Debt | 1.75M |
| Net Cash | -227,202 |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | -365,966 |
| Book Value Per Share | -0.55 |
| Working Capital | -1.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 5.03M |
| Free Cash Flow | -7.25M |
| FCF Per Share | -$5.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -15,166.68% |
| Pretax Margin | -14,220.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.80% |
| Shareholder Yield | -16.80% |
| Earnings Yield | -803.79% |
| FCF Yield | -234.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 7, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:75 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -18.93 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |